ページ3 - 最高の骨髄移植術医師 - トップ88名の医師

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Professor. Hematology and Transplantology Specialist

ハダサ医療センターの血液学部門の責任者
教授

専門分野

• 血液学的疾患の分子診断
• 悪性血液疾患
• 骨髄移植
• 遺伝子治療
• 免疫学

キャリアの初めに、ディナ・ベン・イェフダはネゲブのベン・グリオン大学の医学部に入学しました。

ニューヨークのメモリアル・スローン・ケタリング癌センターで3年間の大学院研修の後、1992年にディナ・ベン・イェフダはハダサに戻りました。

2000年4月には、教授は血液学部門のディレクターに任命されました。

2017年、ベン・イェフダ教授はハダサ医学校の23代目の学部長となり、70年以上の歴史を持つ医療学部を率いる初の女性となりました。

ディナ・ベン・イェフダ教授は、戦闘中に戦死したまたは行方不明となった兵士に関する情報収集の取り組みで、参謀総長賞を受賞した初の女性兵士です。

最近、ディナ・ベン・イェフダはダニエル・ゾンネンフェルド基金から「Heart with the Heart受賞」を受賞しました。この名誉ある賞は、専門の枠を超えて患者に奉仕し、医学倫理以上のことを成し遂げた医師と看護師に与えられます。

専門協会への加入:

イスラエル血液学会

国際血液学会

イスラエル血液腫瘍学会

国際血液腫瘍学会

Dr. Polina Stepensky is an expert in saving the lives of children, performing over 3,500 bone marrow transplants and being recognized by Forbes as one of the best doctors in 2018. Here are her key takeaways:

• 20 years of practice
• Perform over 3,500 bone marrow transplants
• Parents of children with rare blood cancer diseases turn to her
• Patients among themselves call her the one who "transplants life"
• Recognized by Forbes as one of the best doctors in 2018

イリーナ・ザイドマン博士はハダサ医療センターの小児血液腫瘍学の専門家です。彼女の主なポイントは次のとおりです：

• ロシアの医学大学小児学部を卒業
• ランバム小児科での小児科レジデンシー
• ランバムでの小児血液腫瘍学フェローシップ
• カナダ、トロントの病気の子供のための病院での小児BMTフェローシップ
• イスラエル小児血液腫瘍学会（ISPHO）の理事会メンバー
• ヨーロッパおよびアメリカのBMT学会のメンバー
• BMTと小児血液腫瘍学の教育に積極的に参加
• 小児骨髄移植の分野でいくつかの記事を発表

Oncohematologist

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

イタリア最大の骨髄移植プログラムの責任者として、サン・ラファエレ病院にて年間90件以上の同種移植を実施。国内トップクラスのリンパ腫専門医。

• 2006年より骨髄移植ユニットを主宰
• ミラノ大学にて血液学および内科学を専攻
• 移植および血液腫瘍に関する研究論文を70件以上発表
• 欧州血液・骨髄移植学会会員

Serdar Bedii Omay教授は、血液学および骨髄移植に関する65本以上の学術論文を発表しており、この分野において豊富な経験を有しています。

• 日本の三重大学医学部にて分子血液学の研鑽を積む
• エーゲ大学およびカラデニズ工科大学において血液学の教授を務める
• 1990年より内科および血液学を専門とする
• 学会発表論文112編および学術会議発表34件の執筆・発表実績を持つ

サン・ラッファエーレ病院リンパ腫ユニット部長 – フェッレーリ教授は、高度臨床研究を目的としたイタリアリンパ腫財団を設立しました。

• 血液腫瘍科副部長、経験年数 28年の経験 年
• リンパ腫治療に関する論文300本以上の著者
• 非ホジキンリンパ腫の研究を専門とする
• 欧州血液学会およびアメリカ血液学会会員